Pregled bibliografske jedinice broj: 1193932
The genetic basis of hepatosplenic T-cell lymphoma
The genetic basis of hepatosplenic T-cell lymphoma // Cancer Discovery, 7 (2017), 369-379 doi:10.1158/2159-8290.CD-16-0330 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1193932 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The genetic basis of hepatosplenic T-cell lymphoma
Autori
Mc Kinney, M ; Moffitt, AB ; Gaulard, P ; Travert, M ; De Leval, L ; Nicolae, A ; Raffield, M ; Jaffe, ES ; Pittaluga, S ; Xi, L ; Hevaican, T ; Iqbal, J ; Belhadj, K ; Delfau-Larue, MH ; Fataccioli, V ; Czader, MB ; Lossos, IS ; Chapman-Fredericks, JR ; Richards, KL ; Fedoriw, Y ; Ondrejka, SL ; Hsi, ED ; Low, L ; Weisenburger, D ; Chan, WC ; Mehta-Shah, N ; Horwitz, S ; Bernal-Mizrachi, L ; Flowers, CR ; Beaven, AW ; Parihar, M ; Baseggio, L ; Parrens, M ; Moreau, A ; Sujobert, P ; Pilichowska, M ; Evens, AM ; Chadburn, A ; Au-Yeung, RKH ; Srivastava, G ; Choi, WWL ; Goodlad, JR ; Aurer, Igor ; Bašić-Kinda, Sandra ; Gascoyne, RD ; Davis, NS ; Li, G ; Zhang, J ; Rajagopalan, D ; Reddy, A ; Love, C ; Levy, S ; Zhuang, Y ; Datta, J ; Dunson, DB ; Dave, SS
Izvornik
Cancer Discovery (2159-8274) 7
(2017);
369-379
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
hepatosplenic T-cell lymphoma
Sažetak
Hepatosplenic T-cell lymphoma (HSTL) is a rare and lethal lymphoma ; the genetic drivers of this disease are unknown. Through whole-exome sequencing of 68 HSTLs, we defi ne recurrently mutated driver genes and copy-number alterations in the disease. Chromatinmodifying genes, including SETD2, INO80, and ARID1B, were commonly mutated in HSTL, affecting 62% of cases. HSTLs manifest frequent mutations in STAT5B (31%), STAT3 (9%), and PIK3CD (9%), for which there currently exist potential targeted therapies. In addition, we noted less frequent events in E ZH2, KRAS , and T P53 . S ETD2 was the most frequently silenced gene in HSTL. We experimentally demonstrated that SETD2 acts as a tumor suppressor gene. In addition, we found that mutations in STAT5B and PIK3CD activate critical signaling pathways important to cell survival in HSTL. Our work thus defi nes the genetic landscape of HSTL and implicates gene mutations linked to HSTL pathogenesis and potential treatment targets. SIGNIFICANCE: We report the fi rst systematic application of whole-exome sequencing to defi ne the genetic basis of HSTL, a rare but lethal disease. Our work defi nes SETD2 as a tumor suppressor gene in HSTL and implicates genes including INO80 and PIK3CD in the disease.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Igor Aurer
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE